Related Experiment Video

Updated: Jun 24, 2026

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension
10:03

Evaluation of Right Ventricular Function in Experimental Models of Pulmonary Arterial Hypertension

Published on: June 27, 2025

N-terminal pro B-type natriuretic peptide predicts mortality in patients with left ventricular hypertrophy

Santiago Garcia1, Muhammad S Akbar, Syed S Ali

  • 1Department of Medicine, Cardiology Section, University of Minnesota, Minneapolis, Minnesota, United States. garci205@umn.edu

International Journal of Cardiology
|April 10, 2009
PubMed

Insights

N-terminal pro B-type natriuretic peptide (NT-proBNP) independently predicts survival in hypertensive patients with left ventricular hypertrophy. Higher NT-proBNP levels indicate increased mortality risk, aiding prognostic assessment.

Area of Science:

  • Cardiology
  • Biomarkers
  • Hypertension Research

Background:

  • Left ventricular hypertrophy (LVH) negatively impacts patient outcomes, particularly in hypertension.
  • The prognostic role of N-terminal pro B-type natriuretic peptide (NT-proBNP) in hypertensive patients with LVH requires further clarification.

Purpose of the Study:

  • To investigate the prognostic value of NT-proBNP in patients diagnosed with hypertension and LVH.

Main Methods:

  • Echocardiography assessed LVH in 232 patients; NT-proBNP levels were determined via blood samples.
  • NT-proBNP levels were analyzed in quartiles; long-term survival data were collected from electronic medical records.

Main Results:

  • Of 232 patients, 105 (45%) had LVH and 130 (56%) had hypertension.
  • In patients with LVH, NT-proBNP levels significantly predicted long-term survival (p=0.01).
  • Elevated NT-proBNP levels (highest quartile) were associated with a twofold increased risk of mortality (OR=2.2, p=0.03), independent of other risk factors.

Conclusions:

  • NT-proBNP serves as an independent predictor of survival in individuals with hypertension and elevated left ventricular mass.
  • NT-proBNP measurement can enhance risk stratification in hypertensive patients with LVH.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...